Key points are not available for this paper at this time.
Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a-n/a.
Tallantyre et al. (Sat,) studied this question.